About Alzamend Neuro™, Inc.

Alzamend Neuro, Inc. is a Delaware corporation headquartered in Tampa, Florida with an office Newport Beach, California.

The mission of Alzamend Neuro is to research, develop and commercial preventions, treatments and cures for Alzheimer’s disease.

The Company is providing hope through the commercialization of existing patented intellectual property while simultaneously funding future treatments through advanced research and development. Alzamend Neuro’s goal is to get a treatment or cure for Alzheimer’s to market at a reasonable cost as quickly as possible.

read more

Current Pipeline

AL001 (aka LiProSal): an ionic cocrystal of lithium that may greatly reduce or eliminate the symptoms of agitation and other endpoints for mild to moderate stage patients diagnosed with Alzheimer’s. We submitted a pre-IND briefing package to the FDA in July 2019. We expect to begin a Phase 1 clinical trial in the second quarter of 2020.

AL002 (aka CAO22W): adjuvant-free therapeutic vaccine intended for use as a treatment or prophylactic for patients diagnosed with Alzheimer’s. We expect to complete preclinical studies and file an IND in the second quarter of 2020.

Join Our Newsletter

Statistics

14 million

The number of Americans projected to be living with Alzheimer’s disease by the year 2050

5.8 million

The number of Americans projected currently living with Alzheimer’s disease in 2019

Every 65 Seconds

 

The estimate how often someone in the United States develops Alzheimer’s disease

Ranks 6th

Leading cause of death in the U.S.

1-in-3

The estimated number of seniors that will die with Alzheimer’s disease or other dementia by 2050

Ranks 5th

Leading cause of death for Americans age 65 and older & Leading cause of disability and poor health for Americans

$290 billion

The estimated cost in 2019 of Alzheimer’s disease to the United States.

$234 billion

The estimated value of unpaid care to Alzheimer’s patients by their caregivers including family and friends

$1.1 trillion

The estimated cost of by 2050 of Alzheimer’s disease to the United States if no treatment or cure is found

1-in-10

The estimated number of Americans age 65 and over that are afflicted in 2019 with Alzheimer’s disease

Women

Are 2 ½ times more likely than men to develop Alzheimer’s disease in the United States

88 million

Estimated number of Americans that will have Alzheimer’s disease or other form of dementia by 2050 if a treatment or cure is not found